{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T07:38:38Z","timestamp":1780645118763,"version":"3.54.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:00:00Z","timestamp":1742342400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:00:00Z","timestamp":1742342400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Rheumatol"],"DOI":"10.1186\/s12969-025-01072-9","type":"journal-article","created":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T09:16:25Z","timestamp":1742375785000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Clinical insights into heterogeneity of rheumatoid factor negative polyarticular juvenile idiopathic arthritis across the world"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8098-9055","authenticated-orcid":false,"given":"Roberta","family":"Naddei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Burrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Ridella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosef","family":"Uziel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Trachana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavla","family":"Dolezalova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrida","family":"Rumba-Rozenfelde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolino","family":"Ruperto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Ravelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Consolaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,19]]},"reference":[{"issue":"9563","key":"1072_CR1","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/S0140-6736(07)60363-8","volume":"369","author":"A Ravelli","year":"2007","unstructured":"Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet. 2007;369(9563):767\u201378.","journal-title":"Lancet"},{"key":"1072_CR2","first-page":"390","volume":"31","author":"RE Petty","year":"2004","unstructured":"Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31:390\u20132.","journal-title":"J Rheumatol"},{"issue":"4","key":"1072_CR3","doi-asserted-by":"publisher","first-page":"683","DOI":"10.3899\/jrheum.160173","volume":"43","author":"A Consolaro","year":"2016","unstructured":"Consolaro A, Ravelli A. Unraveling the phenotypic variability of juvenile idiopathic arthritis across races or geographic areas - key to understanding etiology and genetic factors? J Rheumatol. 2016;43(4):683\u20135.","journal-title":"J Rheumatol"},{"key":"1072_CR4","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S2352-4642(19)30027-6","volume":"3","author":"A Consolaro","year":"2019","unstructured":"Consolaro A, Giancane G, Alongi A, van Dijkhuizen EHP, Aggarwal A, Al-Mayouf SM, et al. Phenotypic variability and disparities in treatment and outcomes of childhood arthritis throughout the world: an observational cohort study. Lancet Child Adolesc Health. 2019;3:255\u201363.","journal-title":"Lancet Child Adolesc Health"},{"issue":"9","key":"1072_CR5","first-page":"1900","volume":"30","author":"A Martini","year":"2003","unstructured":"Martini A. Are the number of joints involved or the presence of psoriasis still useful tools to identify homogeneous disease entities in juvenile idiopathic arthritis? J Rheumatol. 2003;30(9):1900\u20133.","journal-title":"J Rheumatol"},{"issue":"3","key":"1072_CR6","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1002\/art.20945","volume":"52","author":"A Ravelli","year":"2005","unstructured":"Ravelli A, Felici E, Magni-Manzoni S, Pistorio A, Novarini C, Bozzola E, et al. Patients with antinuclear antibody-positive juvenile idiopathic arthritis constitute a homogeneous subgroup irrespective of the course of joint disease. Arthritis Rheum. 2005;52(3):826\u201332.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"1072_CR7","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1002\/art.30076","volume":"63","author":"A Ravelli","year":"2011","unstructured":"Ravelli A, Varnier GC, Oliveira S, Castell E, Arguedas O, Magnani A, et al. Antinuclear antibody-positive patients should be grouped as a separate category in the classification of juvenile idiopathic arthritis. Arthritis Rheum. 2011;63(1):267\u201375.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"1072_CR8","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41584-021-00590-6","volume":"17","author":"PA Nigrovic","year":"2021","unstructured":"Nigrovic PA, Colbert RA, Holers VM, Ozen S, Ruperto N, Thompson SD, et al. Biological classification of childhood arthritis: roadmap to a molecular nomenclature. Nat Rev Rheumatol. 2021;17(5):257\u201369.","journal-title":"Nat Rev Rheumatol"},{"issue":"11","key":"1072_CR9","doi-asserted-by":"publisher","first-page":"3249","DOI":"10.1002\/art.27657","volume":"62","author":"MG Barnes","year":"2010","unstructured":"Barnes MG, Grom AA, Thompson SD, Griffin TA, Luyrink LK, Colbert RA, et al. Biologic similarities based on age at onset in oligoarticular and polyarticular subtypes of juvenile idiopathic arthritis. Arthritis Rheum. 2010;62(11):3249\u201358.","journal-title":"Arthritis Rheum"},{"key":"1072_CR10","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1002\/art.21119","volume":"52","author":"S Viola","year":"2005","unstructured":"Viola S, Felici E, Magni-Manzoni S, Pistorio A, Buoncompagni A, Ruperto N, et al. Development and validation of a clinical index for assessment of long-term damage in juvenile idiopathic arthritis. Arthritis Rheum. 2005;52:2092\u2013102.","journal-title":"Arthritis Rheum"},{"key":"1072_CR11","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00296-018-3944-1","volume":"38","author":"F Bovis","year":"2018","unstructured":"Bovis F, Consolaro A, Pistorio A, Garrone M, Scala S, Patrone E, et al. Cross-cultural adaptation and psychometric evaluation of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) in 54 languages across 52 countries: review of the general methodology. Rheumatol Int. 2018;38:5\u201317.","journal-title":"Rheumatol Int"},{"issue":"5","key":"1072_CR12","doi-asserted-by":"publisher","first-page":"938","DOI":"10.3899\/jrheum.100930","volume":"38","author":"G Filocamo","year":"2011","unstructured":"Filocamo G, Consolaro A, Schiappapietra B, Dalpr\u00e0 S, Lattanzi B, Magni-Manzoni S, et al. A new approach to clinical care of juvenile idiopathic arthritis: the Juvenile Arthritis Multidimensional Assessment Report. J Rheumatol. 2011;38(5):938\u201353.","journal-title":"J Rheumatol"},{"issue":"5","key":"1072_CR13","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1002\/art.24516","volume":"61","author":"A Consolaro","year":"2009","unstructured":"Consolaro A, Ruperto N, Bazso A, Pistorio A, Magni-Manzoni S, Filocamo G, et al. Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheum. 2009;61(5):658\u201366.","journal-title":"Arthritis Rheum"},{"issue":"12","key":"1072_CR14","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1136\/annrheumdis-2012-202031","volume":"72","author":"F McErlane","year":"2013","unstructured":"McErlane F, Beresford MW, Baildam EM, Chieng SE, Davidson JE, Foster HE, et al. Validity of a three-variable Juvenile Arthritis Disease Activity score in children with new-onset juvenile idiopathic arthritis. Ann Rheum Dis. 2013;72(12):1983\u20138.","journal-title":"Ann Rheum Dis"},{"key":"1072_CR15","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1002\/acr.22393","volume":"66","author":"A Consolaro","year":"2014","unstructured":"Consolaro A, Negro G, Gallo MC, Bracciolini G, Ferrari C, Schiappapietra B, et al. Defining criteria for disease activity states in nonsystemic juvenile idiopathic arthritis based on a three-variable juvenile arthritis disease activity score. Arthritis Care Res (Hoboken). 2014;66:1703\u20139.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"11","key":"1072_CR16","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1002\/art.41879","volume":"73","author":"C Trincianti","year":"2021","unstructured":"Trincianti C, Van Dijkhuizen EHP, Alongi A, Mazzoni M, Swart JF, Nikishina I, et al. Definition and validation of the American College of Rheumatology 2021 Juvenile Arthritis Disease activity score cutoffs for disease activity states in juvenile idiopathic arthritis. Arthritis Rheumatol. 2021;73(11):1966\u201375.","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"1072_CR17","doi-asserted-by":"publisher","first-page":"190","DOI":"10.3899\/jrheum.180168","volume":"46","author":"A Martini","year":"2019","unstructured":"Martini A, Ravelli A, Avcin T, Beresford MW, Burgos-Vargas R, Cuttica R, et al. Toward new classification criteria for juvenile idiopathic arthritis: first steps, Pediatric Rheumatology International Trials Organization International Consensus. J Rheumatol. 2019;46(2):190\u20137.","journal-title":"J Rheumatol"},{"issue":"7","key":"1072_CR18","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1093\/rheumatology\/kew021","volume":"55","author":"F McErlane","year":"2016","unstructured":"McErlane F, Foster HE, Carrasco R, Baildam EM, Chieng SE, Davidson JE, et al. Trends in paediatric rheumatology referral times and disease activity indices over a ten-year period among children and young people with juvenile idiopathic arthritis: results from the childhood arthritis prospective study. Rheumatology (Oxford). 2016;55(7):1225\u201334.","journal-title":"Rheumatology (Oxford)"}],"container-title":["Pediatric Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-025-01072-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12969-025-01072-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-025-01072-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T09:16:28Z","timestamp":1742375788000},"score":1,"resource":{"primary":{"URL":"https:\/\/ped-rheum.biomedcentral.com\/articles\/10.1186\/s12969-025-01072-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,19]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1072"],"URL":"https:\/\/doi.org\/10.1186\/s12969-025-01072-9","relation":{},"ISSN":["1546-0096"],"issn-type":[{"value":"1546-0096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,19]]},"assertion":[{"value":"16 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participating centers to EPOCA study obtained approval from their respective ethics committee and consent\/assent from parents\/patients based on existing national regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Granted by all authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MB, FR, YU, MT, PD and IRR have nothing to disclose. RN has received support for attending meetings and\/or travel from SOBI. NR has received honoraria for consultancies or speaker bureaus from the following pharmaceutical companies in the past 3 years: 2 Bridge, Amgen, AstraZeneca, Aurinia, Bayer, Brystol Myers and Squibb, Celgene, inMed, Cambridge Healthcare Research, Domain Therapeutic, EMD Serono, Glaxo Smith Kline, Idorsia, Janssen, Eli Lilly, Novartis, Pfizer, Sobi, UCB. The IRCCS Istituto Giannina Gaslini (IGG), where NR works as full-time public employee, has received contributions from the following industries in the last 3 years: Bristol Myers and Squibb, Eli-Lilly, F Hoffmann-La Roche, Novartis, Pfizer, Sobi. This funding has been reinvested for the research activities of the hospital in a fully independent manner, without any commitment with third parties. AR has reports honoraria for consultancies or speaker bureaus (<\u200910.000 USD each) from AbbVie, Angelini, BMS, Pfizer, Hoffman LaRoche, Novartis, Pfizer, Reckitt Benckiser in the past 3 years. AR has received payment for expert testimony from Abbvie, Novartis, Pfizer in the past 3 years. AC reports Investigator initiated research grant from Pfizer and Alfa Sigma and speaker\u2019s bureaus from Pfizer and Abbvie.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"30"}}